AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02014467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection
Study NCT02014467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental Calcium
Description: Oral, at least 600 mg
Study NCT02014467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Elemental Calcium
Description: Oral, at least 600 mg
Study NCT02014467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral, at least 400 IU
Study NCT02014467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Oral, at least 400 IU
Study NCT03524599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention municipality
Description: In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
Study NCT03321643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03321643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT03321643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03321643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04956822 — intervention group
Intervention type: OTHER
Intervention: Functional scores
Description: depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores
Study NCT03321643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET-CT
Study NCT03321643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT02614833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMP321 (eftilagimod alpha)
Description: In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
Study NCT02614833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
Study NCT02614833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be given in both treatment arms (classified as Non IMP)
Study NCT02614833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given in both treatment arms (classified as Non IMP)
Study NCT03321643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03321643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT01546519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: oral repeating dose of 150 mg once daily
Study NCT03500367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: rapamycin, 2 mg a day, orally ,for 3months
Study NCT03321643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study NCT03321643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01871376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal aflibercept injection 2.0mg
Description: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
Study NCT01472926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
Study NCT01472926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase
Description: Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
Study NCT05403619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: Cardiac Ultrasound in order to explore the causes of shortness of breath
Study NCT03379155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based self-help program
Description: The intervention provided is based on the principles of cognitive behavioral therapy (CBT) (Bachem \& Maercker, 2013). The manual integrates a variety of approaches validated as treatments for PTSD, anxiety disorders, or depression; the selection focuses on exercises which are intended to target the main symptoms of AjD, namely preoccupations (e.g. constant rumination, excessive worry about the stressor) and failure to adapt (e.g. sleep disturbance, difficulties concentrating, loss of interest in previously enjoyable activities).
Study NCT01235949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
Study NCT04509388 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Composition of Sports Drink
Description: The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
Study NCT04509388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Composition of Sports Drink
Description: The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
Study NCT00954447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, identical to Linagliptin tablet
Study NCT00954447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: intended final marketed dose
Study NCT03309202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: 25 mg dose
Study NCT03345914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Treatment: Moisturizers
Description: All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
Study NCT03473171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal non-invasive ventilation with RAM cannula
Description: Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
Study NCT02153333 — intervention group
Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
Study NCT04459728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 1: Exercise
Description: Daily wellness element focusing on Exercise; adherence documented online daily
Study NCT01235949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
Study NCT02457611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT01235949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-008
Description: Drug: CA-008 4.2 mg reconstituted in saline
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg IV at the onset of anesthesia
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 30 mg IV at the onset of anesthesia
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen IV
Description: 1 g at the onset of anesthesia
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen IV
Description: 1 g at the onset of anesthesia
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg IV fentanyl administered at the onset of anesthesia and additional 50 mcg near the end of surgery
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 0.25% 30 mL (75 mg) prior to surgery
Study NCT04956822 — intervention group
Intervention type: DEVICE
Intervention: MINUX
Description: MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.
Study NCT03007745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: autoadjusting continuous positive airway pressure
Description: Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
Study NCT03007745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoadjusting continuous positive airway pressure
Description: Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
Study NCT00603980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled placebo + oral placebo
Description: Inhaled Staccato placebo + oral placebo
Study NCT00921284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 9/00
Description: Same volume as in the dexmedetomidine group
Study NCT00921284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
Study NCT00760526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitor
Description: Daily use of a continuous glucose monitor
Study NCT00760526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home blood glucose monitor
Description: Home monitoring 3 or more times a day
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% 30 mL (75 mg) prior to surgery
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl
Description: 1.5% 12 mL at the end of surgery
Study NCT03699202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
Study NCT03699202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
Study NCT02385071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 150 milligram (mg) SMV capsule with water under fed conditions.
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg PO bid each day postoperative
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Oral
Description: 1 g postoperative
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 2% 15 mL at the end of surgery
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: 2% 15 mL at the end of surgery
Study NCT03885596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Bupivacaine liposome injection suspension
Study NCT02716324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Manager CM)
Description: The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
Study NCT02716324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Portal
Description: The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
Study NCT02716324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD Portal
Description: The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
Study NCT01465243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
Study NCT01006551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: 20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
Study NCT02983370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minicraniotomy
Description: The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
Study NCT02385071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
Study NCT04302519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dental pulp mesenchymal stem cells
Description: On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.
Study NCT05171218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music & Auditory Beat Stimulation
Description: Listening to calm music and auditory beat stimulation Participants listened to calm music with theta auditory beat stimulation for 24 minutes
Study NCT05171218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Alone
Description: Listening to calm music Participants listened to calm music for 24 minutes
Study NCT05171218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Auditory Beat Stimulation
Description: Listening to theta auditory beat stimulation Participants listened to theta auditory beat stimulation for 24 minutes
Study NCT05171218 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pink Noise
Description: Listening to pink noise Participants listened to pink noise for 24 minutes
Study NCT02526641 — intervention group
Intervention type: PROCEDURE
Intervention: Functional Hepatic Nitrogen Clearance (FHNC)
Study NCT02526641 — intervention group
Intervention type: PROCEDURE
Intervention: Galactose Elimination Capacity (GEC)
Study NCT02526641 — intervention group
Intervention type: PROCEDURE
Intervention: Liver vein catheterization
Study NCT03168646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wafer procedure
Description: wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
Study NCT03168646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopy and ulnar shortening osteotomy
Description: wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
Study NCT02385071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).
Study NCT00603980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 0.5 mg
Description: Inhaled Staccato alprazolam 0.5 mg + oral placebo
Study NCT02385071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: \*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fed conditions.
Study NCT02385071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
Study NCT02385071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: 3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3\*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
Study NCT03914690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
Study NCT03914690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
Study NCT00865748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl 500 mg tablets, single dose
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions
Study NCT00865748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOPHAGE® XR 500 mg tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study NCT01418456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotics
Description: A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
Study NCT01040247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embryo Transfer
Description: In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.